Deutsche Bank Stick to Their Buy Rating for Qiagen NV


Deutsche Bank (DE:DBKGn) analyst Falko Friedrichs maintained a Buy rating on Qiagen (NYSE:QGEN) NV on Wednesday, setting a price target of EUR60, which is approximately 44.08% above the present share price of $49.29.

Friedrichs expects Qiagen NV to post earnings per share (EPS) of $0.39 for the third quarter of 2020.

The current consensus among 15 TipRanks analysts is for a Moderate Buy rating of shares in Qiagen, with an average price target of $56.55.
The analysts price targets range from a high of $71.02 to a low of $46.16.

In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $443.25 million and a net profit of $139.89 million. The company’s market cap is $11.28 billion.

According to, Deutsche Bank analyst Falko Friedrichs is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 4.5% and a 49.15% success rate.

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.


About Author

Leave A Reply